Researchers are testing new blood-based markers to estimate who may develop Alzheimer’s and when symptoms might appear. The work looks promising for earlier detection and better trial enrollment, but limits on accuracy, broad validation, and how results are used in clinical care remain real concerns.
Scientists are zeroing in on p-tau217, a form of tau protein that builds up in brains affected by Alzheimer’s. A large, NIH-funded study tracked more than 600 symptom-free older adults and used repeated blood measures to try to forecast when cognitive symptoms would begin. The metric is attractive because a blood draw is far cheaper and easier than PET scans or repeated imaging sessions.
Across that group, the models predicted symptom onset with a median absolute error of about three to four years, which is useful for research but imperfect for individual medical decisions. Higher p-tau217 levels tended to line up with earlier emergence of symptoms, suggesting the marker tracks disease biology long before people notice problems. Still, the signal is probabilistic rather than definitive.
The age at which p-tau217 becomes elevated appears to shape how quickly symptoms follow. In the study, elevation at age 60 typically corresponded to symptom onset roughly 20 years later, while elevation at age 80 was linked to symptoms in about 11 years. Those patterns were reported in Nature Medicine, but investigators stress the need to test the models in wider, more diverse populations before routine clinical use.
“In the near term, these models will accelerate our research and clinical trials,” said lead investigator Dr. Suzanne Schindler at Washington University in St. Louis. The main immediate value seems to be smarter recruitment and staging for trials of therapies designed to slow or prevent Alzheimer’s progression.
With more treatments moving through approvals, clinicians and families are hungry for reliable biomarkers to confirm pathology and guide care. The tests are easier to scale than PET imaging and could speed up diagnosis when used alongside clinical evaluations. That said, biomarker confirmation is only one piece of a larger assessment.
There are already two FDA-cleared plasma assays on the market, including the Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio and the Roche Elecsys pTau181 Plasma. Each clearance comes with limits on intended use, generally focused on symptomatic adults 55 and older or for initial assessment in primary care when cognitive decline is present. Other lab-developed options are appearing too, and they are not interchangeable.
The Alzheimer’s Association recommends using blood biomarkers mainly in specialty settings for patients who already show cognitive impairment. “We do not recommend the use of blood biomarker tests in people who are not experiencing symptoms,” she said. That caution reflects the current evidence base and the risk of overdiagnosis if tests are used indiscriminately.
Diagnosing Alzheimer’s is typically a “multi-step process” that combines clinical history, cognitive testing, imaging when appropriate, and biomarker data. “Current Alzheimer’s blood biomarker tests are not a standalone test to diagnose Alzheimer’s disease – such a thing does not yet exist,” she said. Blood results must be interpreted in context to avoid misleading patients and families.
Accuracy varies among available assays, and false positives can cause real harm through unnecessary anxiety and interventions. Conditions such as chronic kidney disease can raise biomarker levels independently of brain disease, underscoring the importance of clinical judgment. Providers need training to spot confounders and to explain what a given result likely means.
Experts emphasize better education for clinicians and patients, plus clear pathways for follow-up after a positive or borderline result. “and they should be ordered and interpreted by a healthcare professional in the context of clinical care.” Ongoing studies aim to refine test performance and to evaluate how these tools change outcomes when applied in routine practice.
Policy moves are also in play to increase access to testing for older adults. The Alzheimer’s Screening and Prevention Act aims to create a route for Medicare to cover FDA-approved or cleared blood biomarker screening tests. Under current law, Medicare coverage for preventive services requires a congressional or guideline-based authorization, which has so far limited broad public insurance support for emerging Alzheimer’s screens.
“Studies in these areas are being conducted, and we expect to learn more at the 2026 Alzheimer’s Association International Conference (AAIC 2026), July 12–15 in London and online,” she added. That future evidence will help decide when and where blood biomarkers belong in everyday clinical care and how to protect patients from premature or inappropriate use of the tests.
